Skip to main content
. 2005 Mar 1;92(5):799–806. doi: 10.1038/sj.bjc.6602449

Table 2. OS and DFS of randomised trials of chemotherapy with RT vs RT alone in locally advanced NPC.

Author Treatment arm OS DFS Median F/U (mo)
Neoadjuvant chemotherapy+RT vs RT alone
VUMCA (1996) a 3 yr – 60% 3 yr – 52% *P<0.01 49
  b 54% 32%  
Hareyama et al (2002) a 5 yr – 60% 5 yr – 55% 49
  b 48% 43%  
Chua et al (1998) a 3 yr – 78% 3 yr – 48% 30
  b 71% 42%  
Ma et al (2001) a 5 yr – 63% 5 yr – 59% *P=0.05 62
  b 56% 49%  
Chua et al (2004)a a 5 yr – 64% *P=0.029 5 yr – 51% *P=0.014 67
  b 58% 43%  
 
Concurrent chemotherapy+RT vs RT alone
Lin et al (2003) a 5 yr – 72% *P<0.01 5 yr – 72% *P<0.01 65
  b 54% 53%  
Chan et al (2002, 2004) a N/A 2 yr – 76% 33
  b N/A 69%  
  a 5 yr – 70% *P<0.05 5 yr – 60% 65
  b 59% 52%  
 
Adjuvant chemotherapy+RT vs RT alone
Rossi et al (1988) a 5 yr – 55% 5 yr – 54% 49.5
  b 61% 50%  
Chi et al (2002) a 4 yr – 59% 4 yr – 58% 43
  b 67% 56%  
 
Neoadjuvant and adjuvant chemotherapy+RT vs RT alone
Chan et al (1995) a 2 yr – 80% 2 yr – 68% 28.5
  b 81% 72%  
 
Concurrent and adjuvant chemotherapy+RT vs RT alone
Al-Sarraf et al (1998, 2001) a 3 yr – 76% *P<0.001 3 yr – 66% *P<0.001 32.4
  b 46% 26%  
  a 5 yr – 67% *P<0.001 5 yr – 58% *P<0.001 60
  b 37% 29%  
Wee et al (2004) a 2 yr – 85% *P=0.02 2 yr – 76% N/A
  b 77% 62%  
Lee et al (2004) a 3 yr – 77% 3 yr – 67% 25
  b 76% 61%  
Kwong et al (2004) a1 3 yr – 89% 3 yr – 70% 32.5
  a2 84% 69%  
  a3 71% 54%  
  b 83% 61%  
*

Statistically significant result (P⩽0.05). a(a1, a2, a3)=combined therapy arm; b=radiotherapy alone arm; OS=overall survival; DFS=disease-free survival; NPC=nasopharyngeal carcinoma; RT=radiotherapy; N/A=not applicable; yr=year; mo=months.

a

This reference is an updated analysis of patients from Chua et al (1998) and Ma et al (2001).